The PD-L1 inhibitor was granted orphan drug status just last month.
A new PD-L1 inhibitor being developed by Pfizer and Merck has been placed on the Fast Track by the FDA. Avelumab is a fully humanized anti-PD-L1 monoclonal antibody being developed for metastatic Merkel cell carcinoma (MCC), an aggressive form of skin cancer. Just last month, the 2 companies published a joint press release announcing the orphan drug designation for avelumab.
The drug continues to be evaluated in a phase 2 study (JAVELIN Merkel 200) to assess safety and efficacy in in patients with metastatic MCC who have progressed after at least 1 prior chemotherapy regimen. The trial program for JAVELIN is simultaneoulsy testing the drug in patients with non-small cell lung cancer who have progressed on platinum-containing doublet therapy and in patients with advanced solid tumors.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More